Cargando…
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia
BACKGROUND: The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory, platform design. FLAIR was successfully amended to include an emerging promising experimental therapy to expedite its assessment, greatly reducing the time to reach the primary outcom...
Autores principales: | Howard, Dena R., Hockaday, Anna, Brown, Julia M., Gregory, Walter M., Todd, Susan, Munir, Tahla, Oughton, Jamie B., Dimbleby, Claire, Hillmen, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792072/ https://www.ncbi.nlm.nih.gov/pubmed/33419469 http://dx.doi.org/10.1186/s13063-020-04971-2 |
Ejemplares similares
-
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
por: Collett, Laura, et al.
Publicado: (2017) -
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
por: Oughton, Jamie B., et al.
Publicado: (2017) -
Designs for adding a treatment arm to an ongoing clinical trial
por: Bennett, Maxine, et al.
Publicado: (2020) -
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial
por: Howard, Dena R., et al.
Publicado: (2016) -
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial
por: Munir, Talha, et al.
Publicado: (2022)